UNSPSC 51385904: Darbufelone mesilate or mesylate

This classification denotes the mesylate form of a cyclooxygenase inhibitor with the molecular formula C18H24N2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 72H8H6K34C, chemically known as 5-((z)-3,5-di-tert-butyl-4-hydroxybenzylidene)-2-imino-4-thiazolidinone. but more generally known as darbufelone, which bears US NIH Compound Identifier 6444826. European Medicines Agency schedules Darbufelone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26843.

UNSPSC 51385904 Darbufelone mesilate or mesylate is a Commodity code nominally identifying a specific pharmaceutical compound, but recent state and local procurement activity tagged to this code does not align with the code's stated scope. The recent opportunities posted under this code cover naloxone procurement, direct-to-manufacturer prescription programs, and generic multi-source pharmaceutical distribution — none of which target darbufelone specifically. State and local governments use this code's family and broader classification to solicit pharmaceutical products, distribution services, and pharmacy benefit management capabilities across multiple issuing bodies including county health departments, state health and human services commissions, and multistate cooperative purchasing alliances.

The three most recent opportunities reflect geographic and structural diversity in pharmaceutical procurement. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2023 response deadline, with quarterly deliveries to the county's community health building. The Texas Health and Human Services Commission posted a Request for Information (HHS0017013) on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers to participating state and local facilities, including Oregon. The code shows recent activity across Florida, Texas, and Minnesota, with mixed issuing bodies spanning county health departments, state health agencies, and cooperative purchasing vehicles. The mismatch between the code's nominal scope and actual procurement activity suggests possible data-classification drift or that this code serves as a broad pharmaceutical-category catch-all in some procurement systems.